Brought to you by 
Vanguard Medica to develop SmithKline's antimigraine drug
Dec 1994
Executive Summary
Vanguard Medica will develop SmithKline Beecham's antimigraine compound SB 209509. Vanguard will also be responsible for all US and European clinical trials, and will receive milestone payments, a share of profits, and US co-promotion rights.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vanguard Medica to develop SmithKline's antimigraine drug
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice